Biel, Switzerland, 16 October 2023 - Mimix Biotherapeutics, a cutting-edge biomedical company, is excited to announce the successful closing of a financial round by onboarding strategic MedTech industry-savvy investors from Asia and Europe. This is a multimillion Swiss franc investment that will enable the clinical translation of FastSkin® treatment, a novel treatment method for chronic and acute wound management. With the proceeds, the company ambition is to enter the US market with its first product for wound care onto the US market in H2 2024.
The funding round was led by prominent industrial investors Heraeus Group, an existing investor, and new investor Asia Jetway Pte, a Singapore-based holding producing and commercializing healthcare solutions in South East Asia through its affiliate companies LandMover, Shangai Keyman, Lader, Healthy Medical, and Jiangsu Lekaibio.
The strategic investors are supporting MimiX's vision to transform the lives of millions of patients suffering from chronic wounds. The investment will accelerate the development and commercialization of FastSkin®, a revolutionary treatment that has the potential to significantly improve patient outcomes and reduce healthcare costs.
"We are thrilled to have the support of Heraeus Group and Asia Jetway, as we work to bring our innovative wound treatment to market," said Marc Thurner, CEO of MimiX. "Their expertise and resources will be invaluable to accelerate go-to-market and internationalization plans.”
The successful completion of the funding marks a significant milestone for MimiX, as it moves closer to achieving its mission of improving chronic wound management. With the support of its investors and stakeholders, the company is well-positioned to bring FastSkin® to market and make a lasting impact on the lives of patients around the world.